The United Kingdom and the United States have hammered out a key trade agreement that will maintain no import taxes on British drug products going into the US market.
Key Provisions of the Pact
Under the terms of the agreement, the UK has agreed to increase spending on drugs through the National Health Service (NHS). This commitment ensures that tariffs on these key goods will remain at zero for a period of the next three years.
This agreement follows previous threats to significantly raise import taxes on patented drug products, with figures floated as high as 100%.
"This arrangement with the Britain bolsters the international landscape for new treatments and establishes long-overdue balance to American-British drug exports," an announcement noted.
Trade Impact
Drugs are one of the UK's biggest exports to the United States, which is clearly the largest market for leading companies like GSK and AstraZeneca.
Trade data show that in the 12 months prior to the third quarter, the UK exported drugs valued at billions to the US. This amount accounted for 17.4% of all goods exports in that timeframe.
"This deal safeguards jobs, increases funding and sets the stage for the UK to become a global hub for medical research," a government official stated.
Detailed UK Commitments
The pact entails several specific pledges from the British government:
- Higher Cost Ceiling: The UK will raise the affordability limit at which it judges new treatments to be too expensive by 25%.
- Higher Drug Budget: There is a goal to increase overall public funding on medicines from 0.3% of the national economy to 0.6% over the coming ten years.
- Refund Ceiling: The amount drug companies must return to the NHS to prevent overspending will be limited at fifteen percent. In the past, repayments were more than 20%.
Broader Context
This agreement comes amid a ongoing dispute between the pharmaceutical industry and the British authorities over drug pricing and NHS adoption.
These tensions were exacerbated by assertions that US patients were charged significantly more for the equivalent treatments than people in the UK and Europe.
In recent months, several significant drug company projects in the UK have been paused or cancelled, while substantial funding commitments have been announced toward US facilities.
A senior figure stated that the NHS needed to invest a greater share on medicines, noting that its budget allocation on drugs had declined as a proportion of its overall budget over the last ten years.
